Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

Item

http://www.wikidata.org/entity/Q43718098

Q43718098

about

Targeted Therapy in Biliary Tract Cancers Targeted therapy in advanced bladder cancer: what have we learned?Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients Multiple mechanisms mediate resistance to sorafenib in urothelial cancer Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review The role of genomics in the management of advanced bladder cancer.Targeting the VEGF pathway in metastatic bladder cancer.New advances in genitourinary cancer: evidence gathered in 2014.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Systemic therapy for metastatic bladder cancer in 2016 and beyond.Incorporating VEGF-targeted therapy in advanced urothelial cancer.Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.A critical review on ramucirumab in the treatment of advanced urothelial cancer.Epigenetic Treatment Options in Urothelial Carcinoma.Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.

P2860

Q26798443-B420741A-8142-44A3-9862-F81AAA1AE14A Q27009469-4C3CCD1C-E078-49E2-B686-B4FB73E579C4 Q28079328-4838E40A-ABEC-479E-B895-C458E43F57F7 Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8D Q35691234-F74B6B6D-B229-4B91-80EC-CC356CA56603 Q35998718-E2619972-1D36-4E02-B91B-E7AC98F58861 Q36270115-BCEC1121-F95B-4A9D-ADA1-C1FDADCA85C3 Q38342992-A4DA2600-D813-4630-8957-1624774E8B09 Q38534167-FF69B3BB-D5E8-46DA-9AC0-180CB1ED64D5 Q38557894-91CC1294-2F85-4BF7-B059-DF3751BC34CD Q38701535-F8EDD85C-E3FB-4053-9016-6637E6E9BBBB Q38753358-24EF5167-6F62-4D6E-8D0E-CA4F9C658B52 Q38756931-2CF54160-C5D2-4D09-A310-3A92EB5FFD7A Q38876486-358C4FC1-3DDC-4A3E-9B44-84A390A70477 Q39394159-AA802983-A29E-4417-BC11-2635F879D013 Q41770394-57F4921B-68ED-4842-996F-77A5465CC3AE Q47787312-E8D580A2-043A-4338-B606-B19AA89603E1 Q50182584-BD558A3B-8EC7-4B81-82F1-D463D69E155D Q53259976-2FCEF83A-0BBB-4E84-AE0D-2E4E351BFAC6

P2860

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

Item

http://www.wikidata.org/entity/Q43718098

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)

@en

Prospective randomized double- ...... asized urothelial cancer: SUSE

@nl

type

Item

label

Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)

@en

Prospective randomized double- ...... asized urothelial cancer: SUSE

@nl

prefLabel

Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)

@en

Prospective randomized double- ...... asized urothelial cancer: SUSE

@nl

P1476

Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)

@en

P2093

Axel Heidenreich

http://www.w3.org/2001/XMLSchema#string

Christian Wülfing

http://www.w3.org/2001/XMLSchema#string

Frank vom Dorp

http://www.w3.org/2001/XMLSchema#string

Hans Heinzer

http://www.w3.org/2001/XMLSchema#string

Heidrun Rexer

http://www.w3.org/2001/XMLSchema#string

Jan Roigas

http://www.w3.org/2001/XMLSchema#string

Joern Kamradt

http://www.w3.org/2001/XMLSchema#string

Margitte Retz

http://www.w3.org/2001/XMLSchema#string

Mark Schrader

http://www.w3.org/2001/XMLSchema#string

Michael Kühn

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.

Phase II study of everolimus in metastatic urothelial cancer.

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

P304

429-436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJU.12437

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Martin Fenner

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24053564

http://www.w3.org/2001/XMLSchema#string

P921

placebo

chemotherapy

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

about

P2860

P2860

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921